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Abstract
Background: Uremic solute concentration increases as Glomerular Filtration Rate (GFR) declines. Weak associations were
demonstrated between estimated GFR (eGFR) and the concentrations of several small water-soluble and protein-bound
uremic solutes (MW,500Da). Since also middle molecular weight proteins have been associated with mortality and
cardiovascular damage in Chronic Kidney Disease (CKD), we investigated the association between several eGFR formulae
and the concentration of Low Molecular Weight Proteins (LMWP) (MW.500Da).
Materials and Methods: In 95 CKD-patients (CKD-stage 2–5 not on dialysis), associations between different eGFR-formulae
(creatinine, CystatinC-based or both) and the natural logarithm of the concentration of several LMWP’s were analyzed: i.e.
parathyroid hormone (PTH), Cystatin C (CystC), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a), leptin, retinol
binding protein (RbP), immunoglobin light chains kappa and lambda (Ig-k and Ig-l), beta-2-microglobulin (b2M), myoglobin
and fibroblast growth factor-23 (FGF-23)).
Results: The regression coefficients (R2) between eGFR, based on the CKD-EPI-Crea-CystC-formula as reference, and the
examined LMWP’s could be divided into three groups. Most of the LMWP’s associated weakly (R2 ,0.2) (FGF-23, leptin, IL-6,
TNF-a, Ig-k, Ig-l) or intermediately (R2 0.2–0.7) (RbP, myoglobin, PTH). Only b2M and CystC showed a strong association (R
2
.0.7). Almost identical R2-values were found per LMWP for all eGFR-formulae, with exception of CystC and b2M which
showed weaker associations with creatinine-based than with CystC-based eGFR.
Conclusion: The association between eGFR and the concentration of several LMWP’s is inconsistent, with in general low R2-
values. Thus, the use of eGFR to evaluate kidney function does not reflect the concentration of several LMWP’s with proven
toxic impact in CKD.
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Introduction
Chronic Kidney Disease (CKD) is an independent risk factor for
mortality and cardiovascular disease (CVD) [1]. As Framingham
risk calculation cannot correctly predict this risk [2,3], other than
traditional risk factors are at play. When kidney function declines,
retention of uremic solutes with potential to cause vessel damage
and other toxic effects, conceivably plays a role in this [4,5].
Glomerular Filtration Rate (GFR) is used to express kidney
function and this can accurately be measured by time-consuming
and labor-intensive methods [6]. In clinical practice, serum
creatinine (Crea) based formulae are used to calculate estimated
GFR (eGFR), which offer an acceptable estimate of measured
GFR (mGFR) [6–9]. However, if possible, mGFR is to be
preferred as it may differ from eGRF especially in the lower GFR
range in a CKD population or in patients with a body constitution
that deviates from the average [6,10]. On the other hand,
measuring GFR by one of these techniques is more costly and
labor-intensive than to determine eGFR. Also, current guidelines
classify CKD based on the Modification of Diet in Renal Disease
study (MDRD) formula [11,12]. More recently, the CKD-EPI-
Crea formula [13] has been proposed as a valid alternative,
especially if eGFR is .60 ml/min/1.73 m2 [9], so that it possibly
will be incorporated into the upcoming KDIGO guideline [14].
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Since concentrations of uremic solutes rise when GFR
deteriorates, it has been thought that GFR reflects the retention
state of the patient and that the elevation of individual solute
concentration of uremic toxins is closely related to the gradual
deterioration of GFR. However, Eloot et al. [15] found very low
regression coefficients between eGFR and several low molecular
weight retention solutes in a CKD population.
The low molecular weight proteins (LMWP) are among the
main representatives of the middle molecules, the third family of
uremic retention solutes [16], and are interesting to study for
their relationship with eGFR as with normal kidney function
they are freely filtered through the glomerular basement
membrane (GBM) and then mainly degraded into amino acids
by the proximal tubules [17]. Furthermore the concentrations of
several of the investigated LMWP’s, such as inflammatory
parameters and FGF-23, are already elevated in patients with a
moderate reduction in GFR [18–21] or in more advanced
CKD [22]. As a consequence, associations between these solutes
and eGFR are often assumed. Assessing the predictive value of
eGFR for their concentration is furthermore also relevant,
because several LMWP’s, such as interleukin-6 (IL-6) [23–26],
tumor necrosis factor-alpha (TNF-a) [27,28], beta-2-microglo-
bulin (b2M) [29,30], and fibroblast growth factor-23 (FGF-23)
[31–33], have been linked to mortality or surrogate outcomes
like vascular damage or progression of kidney failure. In
addition, active removal of middle molecules by dialysis has
been associated with better outcome [34].
Therefore, we investigated in a CKD population whether the
concentration of several LMWP’s would associate with eGFR,
calculated by several eGFR formulae.
Materials and Methods
Ethics Statement
The study was approved by the local ethical committee (Comite´
Consultatif de Protection des Personnes dans la Recherche
Biome´dicale (CCPPRB) de Picardie, CHU Amiens, Amiens,
France) and performed in accordance to the Declaration of
Helsinki. Written informed consent was obtained from all patients.
Study Population
This evaluation is a planned sub-analysis of a study undertaken
over an 18-month period (January ’06- June ’07), which screened
150 Caucasian patients with prevalent CKD stage 2–5D from the
Nephrology Department at Amiens University Hospital, in which
uremic retention solutes in relation to clinical outcomes were
analyzed [23,35–37].
All patients were over 40 years old and had a confirmed
diagnosis of CKD (two previous eGFR measures of ,90 ml/min,
calculated by the Cockcroft-Gault formula with an interval of 6–9
months) [38]. Exclusion criteria were chronic inflammatory
disease, atrial fibrillation, complete heart block, abdominal aorta
aneurysm, an aortic and/or femoral artery prosthesis, primary
hyperparathyroidism, kidney transplantation, and any acute
cardiovascular event in a 3 month period prior to screening for
inclusion.
From the 140 patients who met the inclusion criteria, 45 were
excluded from the current study because of hemodialysis
treatment, which has an impact on solute concentration and on
eGFR. The 95 patients, included in this study, were classified in
CKD stages according to the CKD-EPI-Crea-CystC formula for
further analysis [8].
Sampling and Laboratory Methods
Blood samples of all patients were collected in the morning from
9 a.m. on, centrifuged, aliquoted, frozen and stored at 280uC.
Cystatin C (CystC) (MW: 13.3 kDa) concentration was determined
by immune-nephelometry (N latex Cystatin CH, Siemens Health-
care, Dade Behring, Marburg, Germany) and that of intact
parathyroid hormone (PTH) (MW: 9.5kDa) with a chemilumino-
metric immunoassay (Liaison N-tact PTH CLIAH, Diasorin,
Stillwater, MN, USA). The determination of retinol binding
protein (RbP) (MW: 21kDa), beta-2-microglobulin (b2M) (MW:
11.8kDa), myoglobin (MW: 17kDa) and total immunoglobulin
light chains kappa (Ig-k) and lambda (Ig-l) (MW: 23kDa) was
performed by laser nephelometry (BNProSpecH, Siemens Health-
care, Dade Behring, Marburg, Germany). ELISA’s were used to
determine the levels of interleukin-6 (IL-6) (MW: 23kDa), tumor
necrosis factor-alpha (TNF-a) (MW: 17kDa) (R&D Systems,
Wiesbaden, Germany), and leptin (MW: 16kDa) (DRG diagnos-
tics, Marburg, Germany). Intact fibroblast growth factor-23 (FGF-
23) (MW: 32kDa), was measured by a two-site (N-terminal and C-
terminal) ELISA (Immunotopics, San Clemente, CA, USA).
Serum creatinine (Crea) (MW: 113Da) was measured colorimet-
rically by standard laboratory methods.
eGFR- Calculation
Six different formulae were used to estimate GFR: the CKD-
EPI formula, based on Crea and CystC (CKD-EPI-Crea-CystC)
eGFR=177.6?Crea20.65?CystC2 0.57?age20.20?0.82 (if female) [8];
two formulae based on Crea alone: the MDRD eGFR=
175?Crea21.154?age20.203?(0.742 if female)?(1.21 if black) [7] and
the CKD-EPI creatinine (CKD-EPI-Crea) eGFR=141.min(-
Crea/k,1)a?max(Crea/k,1) 21.209?0.993Age?1.018 (if female)?1.159
(if black) (k: 0.7 if female, 0.9 if male; a: 20.329 if female, 20.411
if male) [13]; and three formulae based on CystC alone: Stevens
eGFR=127.7?CystC21.17?age20.13?0.91 (if female)?1.06 (if black)
[8], Le Bricon eGFR= [78?(1/CystC)]+4 [39] and Rule
eGFR=66.8?(CystC)21.3 [40].
Statistical Analysis
The data are expressed as mean 6 standard deviation and
analysed by ANOVA if they were normally distributed. For data
that were not normally distributed, median with interquartile
range and Kruskall-Wallis test were used. Linear regressions and
Pearson correlations were calculated on semi-logarithmic (LN)
concentrations as a function of eGFR. Multifactorial analysis was
performed to correct for well-known influencing factors for the
concentration of several solutes. The regression model of CystC,
b2M, IL-6, TNF-a, Ig-k and Ig-l was adjusted for C-reactive
protein (CRP), the one of FGF-23 and PTH for calcium,
phosphorus and vitamin D-supplementation, the one of leptin
for body mass index (BMI) and gender, and the one of RbP for
BMI, 1/CRP and diabetes mellitus. A P,0.05 was considered as
statistically significant. All statistical analyses were performed using
SPSS Statistics 19 (SPSS Inc, Chicago, IL) for Windows (Microsoft
Corp, Redmond, WA).
Results
Ninety-five patients at different stages of CKD were included:
11.5% CKD stage 2, 39.0% CKD stage 3, 39.0% CKD stage 4,
and 10.5% CKD stage 5 not on dialysis. Table 1 summarizes the
demographic and clinical characteristics of the study population.
The concentrations of the studied LMWP’s, except for the
immunoglobulin light chains, increased progressively with declin-
ing kidney function (Table 2).
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Our analysis primarily focused on the linear regression analysis
with the natural logarithm (LN) of the concentration of each
studied uremic retention solute concentration as dependent
variable and the CKD-EPI-Crea-CystC eGFR as independent
variable. This formula was chosen as reference because it is
considered as one of the most accurate ones at this time while it
incorporates both Crea and CystC, in contrast to all other studied
formulae which are based on either Crea or CystC [8].
Associations between eGFR and LMWP’s were expressed as
regression coefficients (R2) and are summarized in table 3 and
figure 1.
The R2-values per individual solute were divergent; according
to these, associations could be arbitrarily divided into three groups:
strong (R2 .0.7), moderate (R2 0.2–0.7) and weak (R2 ,0.2)
(Figure 1). As expected, CystC (R2= 0.828) was strongly associated
as it is one of the used parameters in the formula. Only b2M
showed a similar association (R2 = 0.770). Retinol binding protein
(RbP), myoglobin and parathyroid hormone (PTH) were moder-
ately associated to eGFR with R2-values of 0.423, 0.303 and
0.231, respectively. The association with eGFR was only weak for
IL-6 (R2 = 0.117), leptin (R2 = 0.084), FGF-23 (R2= 0.058) and
TNF-a (R2 = 0.056). There was even no association for immuno-
Table 1. Main demographic and clinical characteristics of the study population (n = 95).
CKD stage P
Stage 2–5 stage 2 stage 3 stage 4 stage 5
Number n (%) 95 (100) 11 (11.5) 37 (39.0) 37 (39.0) 10 (10.5)
eGFR (ml/min/1.73m2) 35618 6968 4369 2264 1163 ,0.001
Age (years) 68612 6568 69612 65613 66615 0.07
Male gender n (%) 59 (62) 9 (82) 24 (65) 22 (60) 4 (40) 0.39
Diabetes Mellitus n (%) 45 (47) 4 (36) 19 (51) 18 (49) 4 (40) 0.50
BMI (kg/m2) 2967 2665 2966 3167 2867 0.28
Cholesterol (mmol/l) 5.061.1 5.460.7 4.661.1 5.361.1 4.660.5 0.02
Triglycerides (mmol/l) 1.961.4 1.760.9 1.660.7 2.461.9 2.261.2 0.06
CRP (mg/l) 3.11 [1.1–6.7] 2.3 [0.7–4.9] 2.8 [1.4–5.0] 3.7 [0.8–8.5] 4.1 [0.4–15.6] 0.696
Albumin (g/l) 38.966.4 40.668.8 38.465.7 39.965.8 33.866.7 0.07
Hemoglobin (g/l) 12.561.7 14.061.2 12.761.5 12.061.6 10.961.4 ,0.001
Calcium (mmol/l) 2.360.1 2.360.1 2.360.1 2.360.2 2.360.2 0.96
Phosphate (mmol/l) 1.260.3 0.960.3 1.160.2 1.460.3 1.560.5 ,0.001
Vit D supplement n (%) 17 (18) 1 (9) 5 (13) 6 (16) 5 (50) 0.06
CKD stages according to the CKD-EPI-Crea-CystC formula. Data are expressed as mean 6 SD, median with interquartile range between square brackets or number for
binary variables, with percentages between brackets per CKD class. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; BMI, body mass index;
Statistical analysis: ANOVA or Kruskall-Wallis; P-values comparing all stages.
doi:10.1371/journal.pone.0044201.t001
Table 2. Concentrations of uremic solutes 6 standard deviation according to CKD-stage (CKD-EPI-Crea-CystC).
CKD stage P- value
stage 2–5 stage 2 stage 3 stage 4 stage 5
CystC (mg/l) 1.960.9 0.960.2 1.460.5 2.460.7 3.560.7 ,0.001
b2M (mg/l) 6.1 [3.2–9.3] 2.6 [2.1–4.6] 3.8 [3.0–5.3] 8.2 [6.7–10.4] 13.9 [12.8–16.4] ,0.001
PTH (pg/ml) 77.0 [42.5–135.5] 39.5 [25.5–44.0] 62.0 [42.0–83.5] 124.0 [74.0–196.0] 111.5 [22.0–173.0] ,0.001
RbP (mg/l) 82.0632.8 52.9615.2 67.0621.8 102.6632.2 95.9631.5 ,0.001
Myoglobin (mg/l) 82.7 [54.9–115.0] 49.9 [32.4–57.4] 72.3 [49.7–104.8] 98.8 [75.4–125.5] 170.5 [62.8–244.0] ,0.001
IL-6 (pg/ml) 2.6 [1.3–5.1] 1.1 [0.4–1.9] 2.2 [1.3–4.0] 3.0 [1.3–5.2] 7.0 [2.2–14.0] 0.001
TNF-a (pg/ml) 3.4 [2.2–4.6] 1.1 [1.1–2.5] 4.1 [2.2–4.6] 2.6 [2.2–5.1] 4.1 [3.1–7.2] 0.016
Leptin (ng/ml) 12.8 [2.0–43.5] 0.56 [,0.48–5.3] 8.5 [2.5–33.4] 21.4 [4.3–59.2] 26.3 [0.7–.105] 0.012
FGF-23 (pg/ml) 30.6 [26.8–34.4] 26.6 [25.8–27.3] 31.5 [27.6–34.5] 30.6 [27.6–34.9] 34.4 [33.1–35.0] 0.007
Ig-k (g/l) 2.6 [2.2–3.0] 2.4 [2.3–2.8] 2.4 [2.1–4.8] 2.8 [2.4–3.0] 2.5 [2.1–3.1] 0.330
Ig-l (g/l) 1.5 [1.3–1.8] 1.5 [1.3–1.7] 1.5 [1.3–1.7] 1.6 [1.4–1.8] 1.2 [1.2–1.8] 0.280
Concentrations are expressed as mean 6 SD or median with interquartile range (between square brackets) as appropriate. CKD: chronic kidney disease, CystC: cystatin
C, b2M: beta-2-microglobulin, PTH: parathyroid hormone, RbP: retinol binding protein, IL-6: interleukin-6, TNF-a: tumor necrosis factor-alpha, Ig-k: immunoglobulin light
chain kappa, Ig-l: immunoglobulin light chain lambda, FGF-23: fibroblast growth factor-23. Statistical analysis: ANOVA or Kruskall-Wallis; P comparing all stages.
doi:10.1371/journal.pone.0044201.t002
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globulin light chain kappa (Ig-k) (R2 = 0.021) and immunoglobulin
light chain lambda (Ig-l) (R2 = 0) (P =N.S.).
Figure 2 shows the dot plots of solute concentrations as a
function of eGFR. Whereas the relation is strong with little scatter
around the linear regression line for b2M (Panel A), the scatter is
much larger for solutes with moderate to weak R2-values, as
illustrated for myoglobin (Panel B), IL-6 (Panel C) and especially
Ig-l (Panel D) for which there is no association at all. The large
standard deviations or wide interquartile ranges of the individual
solute concentrations per CKD-stage also illustrate the large inter-
individual variability of LMWP concentration within the same
eGFR-range (Table 2).
In addition we analyzed the correlation coefficients between the
concentrations of the different LMWP and eGFR (CKD-EPI-
Crea-CystC) in the group CKD stage 2–3 versus CKD stage 4–5.
The correlation between RbP, PTH, myoglobin, FGF-23 and
eGFR was significant in CKD-stage 2–3 while not in CKD stage
4–5. For the other investigated solutes, the R2-values in CKD
stage 2–3 and CKD stage 4–5 were more confirm to each other.
The respective R2-values are summarized in table 4.
In a second step, the same analysis was performed with the
other formulae under evaluation and compared to the results with
the CKD-EPI-Crea-CystC-formula. The R2-values between all
eGFR formula and individual solutes were strikingly similar with
only one exception (Table 3). b2M was only moderately associated
to Crea-based eGFR, with R2-values of approximately 0.55, as
compared to CystC-based eGFR (R2 .0.8). In this way b2M
followed the same pattern as CystC, for which this discrepancy
could be attributed to whether CystC was included as a factor in
the formula or not. Considering the other studied LMWP’s, only
PTH showed a moderately similar trend, with R2 approximately
0.27 compared to R2 approximately 0.13, with CystC- or Crea-
based eGFR-formulae, respectively.
Finally, we performed multifactorial regression analysis for the
different LMWP’s with adjustment for several relevant variables.
However, only two models induced a marked increase in R2-value:
for leptin the association rose from weak to moderate when BMI
was added to the regression model (R2 from 0.084 to 0.346), with
BMI as an independent predictor for the leptin concentration.
Likewise, after adjustment for CRP, IL-6 became moderately
associated with eGFR (R2 from 0.117 to 0.305 after adjustment).
For all other solutes there was no change in R2. (Data not shown).
Discussion
We analyzed the linear regression coefficients between the
concentrations of several LMWP’s retained in CKD and different
eGFR-formulae in a CKD population, stage 2–5 not on dialysis.
As a main finding, the R2-values diverged considerably, ranging
from high, R2 .0.7, to low, R2 ,0.2. The majority of the
evaluated LMWP’s associated weakly (R2 ,0.2 for IL-6, TNF-a,
FGF-23 and leptin) or moderately (R2: 0.2–0.7 for RbP,
myoglobin and PTH). There was no correlation at all for the
immunoglobulin light chains. Only CystC and b2M showed a
strong association with eGFR (R2 .0.7) (Figure 1, Table 3).
Although in some studies a correlation was sought for individual
LMWP’s and eGFR of mGFR, this present study seeked out the
association of the concentration of several LMWP’s and eGFR
formulae together allowing their comparison.
The R2-values for the weakly and moderately associating
LMWP’s did not differ substantially whether eGFR was calculated
with the CKD-EPI-Crea-CystC-formula [8], the Crea-based
formulae (MDRD [7] and CKD-EPI-Crea [13]), or the three
different CystC-based formulae, (Stevens [8], Rule [40] and Le
Bricon [39]) (Table 3). These low regression coefficients can
partially be attributed to the known limitations of eGFR, as an
index of mGFR [6,41]. However in at least four other studies,
almost identical low regression coefficients were found between
mGFR, assessed with different techniques, and the concentration
Figure 1. Regression coefficients between LN of studies
LMWP’s and eGFR. The coefficients of the linear regression analysis
between the natural logarithm of the studied low molecular weight
protein concentrations and estimated Glomerular Filtration Rate,
according to CKD-EPI-Crea-CystC, can be divided into 3 groups: strong
(R2 .0.7), moderate (R2 0.2–0.7) and weak (R2 ,0.2). The dashed lines
indicate R2 = 0.2 and 0.7. All correlations were significant except for Ig-k
and Ig-l. LN: natural logarithm, LMWP: low molecular weight protein,
eGFR estimated glomerular filtration rate, R2: regression coefficient, Cyst
C: Cystatin C, b2M: beta-2-microglobulin, RbP: retinol binding protein,
PTH: parathyroid hormone, IL-6: interleukin-6, FGF-23: fibroblast growth
factor-23, TNF-a: tumor necrosis factor-alpha, Ig-k: immunoglobulin
light chain kappa, Ig-l: immunoglobulin light chain lambda.
doi:10.1371/journal.pone.0044201.g001
Table 3. Regression coefficients of LMWP’s and different
eGFR formulae.
R2
CKD-EPI-
Cr-CystC MDRD
CKD-
EPI-Cr Stevens Le Bricon Rule
R2 .0.7
Cyst C 0.828 0.572 0.569 0.920 0.939 0.902
b2M 0.770 0.559 0.549 0.838 0.855 0.820
R2 0.2–0.7
RbP 0.423 0.348 0.343 0.383 0.397 0.390
Myoglobin 0.303 0.246 0.262 0.287 0.297 0.293
PTH 0.231 0.130 0.132 0.279 0.274 0.276
R2 ,0.2
IL-6 0.117 0.090 0.097 0.126 0.127 0.123
Leptin 0.084 0.056 0.059 0.092 0.065 0.065
FGF-23 0.058 0.008 0.008 0.095 0.101 0.094
TNF-a 0.056 0.043 0.044 0.066 0.058 0.061
Ig-k 0.021 0.021 0.020 0.016 0.015 0.011
Ig-l 0.000 0.000 0.000 0.001 0.001 0.001
LMWP: Low Molecular Weight Protein, R2: regression coefficient, eGFR:
estimated glomerular filtration rate, CKD-EPI-Crea-CystC: CKD-EPI formula based
on creatinine and cystatin C, MDRD: Modification of Diet in Renal Disease
formula, CKD-EPI-Crea: CKD-EPI formula based on creatinine. CystC: cystatin C,
b2M: beta-2-microglobulin, RbP: retinol binding protein, PTH: parathyroid
hormone, IL-6: interleukin-6, FGF-23: fibroblast growth factor-23, TNF-a: tumor
necrosis factor-alpha, Ig-k: immunoglobulin light chain kappa, Ig-l:
immunoglobulin light chain lambda.
doi:10.1371/journal.pone.0044201.t003
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of RbP (R2 0.16) [42], myoglobin (R2 0.38) [43], leptin (R2 0.0004)
[44] and FGF-23 (R2 0.09) [45] as in our study, be it that
transformation of the concentrations varied from study to study. In
addition, the imperfect reflection of true GFR by eGFR can
explain that regression coefficients are substantially lower than 1,
but not that the range in between individual molecules is so
discordant, whereas per molecule they are almost identical
(Table 3, Figure 1). There was also an unpredictable and large
variability in concentrations of different solutes within each eGFR
stratum (Table 2). These data suggest another reason for the
sometimes deceiving associations than a discrepancy among
mGFR and eGFR, namely that uremic solute concentration
depends on other factors than GFR as well. In this way, our study
corroborates findings in an earlier study with small water-soluble
and protein-bound compounds [15,46].
These results are somewhat unexpected from a physiological
point of view as the renal clearance of these LMWP’s depends to a
large extent on GFR alone. All these LMWP’s are freely filtered
through the GBM, followed, at normal physiological concentra-
tions, by an almost entire uptake by the proximal tubules via a
receptor-mediated process to be degraded subsequently into
amino acids in the tubular lysosomes [17,47]. In this way, the
proximal tubulus plays an important role in LMWP metabolism
but without a direct contribution to their renal clearance;
regarding the latter, GFR is the rate limiting step. This probably
explains why we did not find any association between eGFR and
the total (free plus bound) immunoglobulin light chains, in contrast
to Hutchison et al who evaluated only free light chains for their
association to eGFR (free Ig-k: R2: 0.52; free Ig-l: R2: 0.44) [48],
as only the free fraction passes the GBM. This is also in contrast to
the small water-soluble and protein-bound uremic toxins, for
which tubular secretion and/or reabsorption play an important
role in renal clearance [15,46].
However, the concentration of small water-soluble and protein-
bound solutes may be further influenced by many other factors as
well, such as enzymatic metabolism, intestinal secretion/absorp-
tion, generation by intestinal flora, diet and changes in distribution
volume [15,46]. It is conceivable that also the concentration of the
Figure 2. Dot plots with best fit linear regression lines for LN of LMWP’s in function of eGFR. Dot plots with best fit linear regression lines
for natural logarithms of b2M, myoglobin, IL-6 and Ig-l, as examples of strongly, moderately and weakly correlating low molecular weight proteins, in
function of estimated Glomerular Filtration Rate, calculated by CKD-EPI-Crea-CystC. The dots represent the individual concentrations and the lines the
best fit linear regression line with the 95% confidence interval. LN: natural logarithm, LMWP: low molecular weight protein, b2M : beta-2-
microglobulin, IL-6: Interleukin-6, Ig-l: immunoglobulin light chain lambda, EPI-Crea-CystC: CKD-EPI formula based on serum creatinine and Cystatin
C, R2: regression coefficient, LN: natural logarithm.
doi:10.1371/journal.pone.0044201.g002
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weakly and moderately correlating LMWP’s depends on other
mechanisms than GFR, which even seem to have more important
weight than GFR. Some known influencing factors such as
changes in generation, homeostatic mechanisms and extra-renal
clearance are summarized in table 5. Multifactorial regression
analysis for the respective LMWP’s including some of these
parameters, increased the R2-value as expected. E.g. for leptin, R2
rose from 0.084 to 0.346 when corrected for BMI,which was an
independent covariate for leptin concentration in a model with
eGFR and BMI. The R2-value between IL-6 and eGFR became
0.305 instead of 0.117, when adjusted for CRP, which, in contrast
to BMI for leptin concentration, did however not independently
predict IL-6 concentration in a model with eGFR and CRP. The
majority of potentially influencing factors did however not
importantly affect the R2-values. This suggests that other than
well known mediators may influence these LMWP concentrations
as well. In more advanced CKD, the influence of confounders, for
example bone metabolism, is probably more important, which
could explain partially that no significant associations were
observed between PTH or FGF-23 and eGFR in CKD stage 4–
5, while they were present in CKD stage 2–3 (table 4). Another
contributing factor to this discrepancy in associations between
CKD stage 2–3 versus CKD stage 4–5 might be purely
mathematical, as the GFR-range in CKD 2–3 (30–90 ml/min/
1.73 m2) is much larger than CKD 4–5 (610–30 ml/min/
1.73 m2).
This study demonstrates that eGFR is not a reliable predictor
of the concentration of most of the evaluated LMWP’s,
although several of them such as IL-6 [23–26], TNF-a
[27,28] and FGF-23 [31–33,49] have been associated with
mortality or with intermediate endpoints, such as vascular
dysfunction or progression to end stage renal disease (ESRD) in
CKD- or hemodialysis patients. Presumably, some of these
solutes, especially if they would be representative for a cluster of
other solutes, might by themselves become useful predictors of
morbidity or mortality in CKD independently from eGFR.
Based on the data collected in the present study, we investigated
the mutual correlations between the concentrations of the
different LMWP’s; however, we could not identify such a
marker, correlating strongly to other LMWP’s without correlat-
ing to eGFR, among the investigated solutes (data not shown).
This question, however, would be worthwhile to be investigated
in larger populations.
In contrast to these weakly and moderately correlating
LMWP’s, there is a remarkable similarity in regression coefficients
between CystC and b2M. First, these molecules are the sole
LMWP’s studied that result in acceptably high associations with
eGFR (Table 3). Second, they associate better with CystC-based
eGFR formulae [8,39,40] than with Crea-based ones [7,13], the
CKD-EPI-Crea-CystC [8] which contains both factors being
intermediate (Table 3). Whereas this is no surprise for CystC
which is included in some formulae and not in others, the pattern
for b2M seems to be identical. This suggests that the kinetics of
both molecules during progression of CKD depend on similar
factors or at least factors with a similar impact on solute
concentration. Of note, some of the non-renal elements with
impact on both concentrations [50,51], like chronic inflammatory
disease or malignancy were among the exclusion criteria of this
study. CystC was a superior marker of the association of GFR with
outcome in a study by Peralta et al., who showed that the
predictive value for mortality or CVD of eGFR ,60 ml/min/
1.73 m2, based on a CystC-based eGFR, was better than eGFR
based on the CKD-EPI-Crea-formula [45]. Recently, in a general
population, CystC and b2M were stronger predictors of mortality,
CVD and evolution to ESRD than eGFR based on the CKD-EPI-
Crea [52].
The present study has some shortcomings. First, the study
population was rather small, with even smaller subgroups per
CKD-stage. Second, we used eGFR which gives only an
approximate value for glomerular filtration in comparison to
more exact methods such as EDTA-clearance. We preferred to use
methods which are applied on a day to day basis. As the
differences in correlations are so striking, it is very likely that these
findings can be extrapolated to GFR in general. The strengths of
this study lie in the fact that several LMWP’s are evaluated
together in the same population for different eGFR formulae
based on Crea, CystC or both.
Our present data, together with the previous ones [15],
showing extremely variable associations between uremic reten-
tion solutes and a surrogate of GFR, suggests that eGFR per se
is an inadequate indicator of the uremic status. This is also
suggested by other studies. In a CKD population, Lilitkarntakul
et al. [53] demonstrated that renal function did not indepen-
dently predict arterial stiffness or endothelial dysfunction while
the uremic retention solutes asymmetric dimethylarginine
(ADMA), isoprostanes or endothelin-A did. In the Initiating
Dialysis Early and Late (IDEAL) trial [54], approximately 75%
of the patients randomized to start dialysis at low eGFR (5–
7 ml/min/1.73 m2), initiated dialysis earlier, mainly because of
uremic symptoms.
In this study, the regression coefficients of different LMWP’s in
relation to eGFR are diverse and in general low. This shows that
other factors than GFR are important for the development of the
‘uremic status’. Further research is needed to evaluate whether
these uremic toxins can be used as biomarkers for the risk
stratification associated to uremic toxicity within the different
CKD-stages and beyond eGFR.
Table 4. Regression coefficients (R2) of the concentration of
LMWP’s and eGFR (CKD-EPI-Crea-CystC) comparing CKD stage
2–3 versus CKD stage 4–5.
R2
CKD stage 2–3
(n=48)
CKD stage 4–5
(n=47)
Cyst C 0.782 0.555
b2M 0.619 0.549
RbP* 0.254 0.001
PTH* 0.195 0.000
Myoglobin* 0.257 0.059
IL-6 0.074 0.117
TNF-a 0.107 0.087
Leptin 0.060 0.001
FGF-23* 0.120 0.033
Ig-k 0.013 0.016
Ig-l 0.001 0.006
LMWP: Low Molecular Weight Protein, eGFR: estimated glomerular filtration
rate, CKD-EPI-Crea-CystC: CKD-EPI formula based on creatinine and cystatin C.
CystC: cystatin C, b2M: beta-2-microglobulin, RbP: retinol binding protein, PTH:
parathyroid hormone, IL-6: interleukin-6, TNF-a: tumor necrosis factor-alpha,
FGF-23: fibroblast growth factor-23, Ig-k: immunoglobulin light chain kappa, Ig-
l: immunoglobulin light chain lambda. *: LMWP’s with a significant correlation
in CKD stage 2–3, but no significant correlation in CKD stage 4–5.
doi:10.1371/journal.pone.0044201.t004
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